VA-REGULA
25.1.2024 08:01:35 CET | Business Wire | Press release
Before adopting an IDV system, it’s imperative to conduct thorough testing, especially for large-scale businesses. However, it is nearly impossible to obtain a reliable set of IDs with real NFC chips (as they contain sensitive personal data) to test-drive the verification process. Besides, it’s not that easy to test both positive and negative verification scenarios without representative ID sampling. Regula’s unique service, Regula NFC TestKit, effectively addresses these issues.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240124863941/en/
An example of a test ID made for Regula NFC TestKit service customers (Photo: Business Wire)
Depending on the particular company’s business needs and market goals, Regula creates a test set of identity documents with NFC chips which are personalized with the data of fictitious identities or those provided by the customer. Apart from the chip, a visual zone and a machine readable zone (MRZ) can also be generated to enable robust cross-checking and system testing. These test IDs are simplified images (with special marks to show that they are not full replicas) of the required pages of the documents the company intends to verify. They are backed up with corresponding templates in a special database version so that the IDV solution can recognize them properly.
By choosing Regula NFC TestKit service, enterprises can benefit from:
- Shorter time to market. Checking and fine-tuning the IDV process with the help of test documents eliminates the necessity of undergoing an early adoption period during which a company could face friction.
- Enhanced IDV solution trial and early problem identification. Regula NFC TestKit service provides the most complete representation of identity documents with multiple data fields. That means any organization can test-drive the complete remote onboarding procedure to address potential issues or vulnerabilities.
- Flexibility and customization. Regula’s service is tailored to the specific needs of any given organization. It is possible to create an NFC-chip-based document sample of any type from any country to test the most likely customer onboarding scenarios.
- Maximum security assurance. Using NFC chips and replicating the data in the MRZ and visual zone ensures that IDV process testing mimics real-life scenarios to get ready to handle customers’ personal data securely.
To enable this service, Regula leverages its unique competencies in forensic examination, as well as IDV software and hardware development. The company personalizes NFC chips with fictitious persons’ data, which is recorded with the help of Regula’s document readers. Importantly, Regula generates all necessary certificate chains for every country in the list, signs the data using these certificates, and provides them to the customer for performing passive authentication. This approach fully imitates the scenario with real NFC chips in real IDs, which allows businesses to take advantage of lifelike document verification when testing their IDV systems.
Regula NFC TestKit is equipped with this functionality thanks to the fact that it is backed by the world’s most comprehensive identity document template database, which is exclusively owned and maintained by Regula. With more than 13,000 templates of IDs from 247 countries and territories, this database makes it possible to imitate nearly any identity document for testing purposes. And thanks to this asset, Regula is able to cover any geography a business may be interested in.
“Businesses currently strive to find suitable solutions to independently test the remote onboarding process of electronic documents, and until now, there have been no offerings on the market to address this gap. With our new service for complete imitation of real IDs, we enable organizations to conduct highly efficient testing to identify and prevent any potential issues prior to the launch of their IDV systems,” says Ihar Kliashchou, Chief Technology Officer at Regula.
Regula NFC TestKit service is provided exclusively for large enterprises that purchase the company’s software solutions. To learn more, contact Regula’s experts.
About Regula
With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed.
Regula was named a Representative Vendor in the Gartner® Market Guide for Identity Verification in 2023.
Learn more at regulaforensics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240124863941/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
Roboverse Reply Impresses at ELROB 2026 With Intelligent Robotic Systems for Critical Missions26.6.2026 10:00:00 CEST | Press release
Roboverse Reply, the Reply Group company specializing in robotics and automation, won the 1st Place in the “Reconnaissance” category and a special prize for “Best Team Effort” at the European Land Robot Trial (ELROB) 2026 in Thun, Switzerland. Teaming up with ELP, a specialist for technical equipment for defusing service, the company demonstrated outstanding performance alongside a field of international participants from June 15 to 19, proving that its autonomous solutions operate reliably under real-world conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626012237/en/ Roboverse Reply won 1st Place in the “Reconnaissance” category and a special prize for “Best Team Effort” at the European Land Robot Trial 2026, proving that its autonomous solutions operate reliably under real-world conditions. ELROB is Europe’s most demanding and established showcase for robotics and unmanned systems, where leading experts from
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
